Secondary prevention of colorectal cancer: Is there an optimal follow-up for patients with colorectal cancer?

Current Colorectal Cancer Reports

Volumn 6, Issue 1, 2010, Pages 24-29

  Carethers, John M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Colon cancer genetics; Colonoscopy; Colorectal cancer; Colorectal cancer screening; Familial cancer; HNPCC (hereditary nonpolyposis colorectal cancer); Lynch syndrome; Secondary prevention

Indexed keywords

PROSTAGLANDIN SYNTHASE INHIBITOR;

BANNAYAN RILEY RUVALCABA SYNDROME; CANCER PATIENT; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON ADENOMA; COLON POLYPOSIS; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COWDEN SYNDROME; FAMILIAL ADENOMATOUS POLYPOSIS; HEALTH CARE PERSONNEL; HEREDITARY MIXED POLYPOSIS SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYPERPLASTIC POLYPOSIS; JUVENILE POLYPOSIS SYNDROME; PEUTZ JEGHERS SYNDROME; POLYPOSIS; REVIEW;

EID: 79952700107     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-009-0038-1     Document Type: Review

References (28)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ: Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, followup study. BMJ 2005, 331:1047.
3. Siegel RL, Jemal A, Ward EM: Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009, 18:1695-1698.
4. Levin B, Lieberman DA, McFarland B, et al.: American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58:130-160. This article outlines the latest screening and surveillance guidelines for colorectal cancer in the United States.
5. Boland CR, Koi M, Chang DK, Carethers JM: The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer 2008, 7:41-52. This article reviews major aspects of diagnosing and caring for patients with Lynch syndrome.
6. Järvinen HJ, Aarnio M, Mustonen H, et al.: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-834. (Pubitemid 30243745)
7. Boland CR, Sinicrope FA, Brenner DE, Carethers JM: Colorectal cancer prevention and treatment. Gastroenterology 2000, 118:S115-S128. (Pubitemid 30094439)
8. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099. This article is a comprehensive review of genetic changes that occur during colorectal cancer development and metastasis.
9. Carethers JM: Intersection of TGFbeta and Wnt signaling pathways in colorectal cancer and metastasis. Gastroenterology 2009, 136:33-36.
10. Chow JYC, Dong H, Quach KT, et al.: TGFb mediates PTEN suppression and cell motility through calcium-mediated PKCa activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008, 294:G899-G905. (Pubitemid 351520064)
11. Chow JYC, Cabral JA, Chang J, Carethers JM: TGF-beta modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer Biol Ther 2008, 7:1694-1699.
12. Jung BH, Beck SE, Cabral J, et al.: Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Gastroenterology 2007, 132:633-644. (Pubitemid 46274658)
13. Jung B, Smith EJ, Doctolero RT, et al.: Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer 2006, 118:2509-2513.
14. Carethers JM, Hawn MT, Greenson JK, et al.: Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998, 114:1188-1195. (Pubitemid 28243904)
15. Jung B, Boland CR, Carethers JM: Neoplasia of the gastrointestinal tract. In Textbook of Gastroenterology, edn 5. Edited by Yamada T, Alpers DH, Kaplowitz N, et al. Philadelphia: Blackwell Publishers; 2008.
16. Carethers JM: Systemic treatment of advanced colorectal cancer - tailoring therapy to the tumor. Ther Adv Gastroenterol 2008, 1:33-42.
17. Huang SC, Lavine JE, Boland PS, et al.: Germline characterization of early-aged onset of hereditary non-polyposis colorectal cancer. J Pediatr 2001, 138:629-635. (Pubitemid 32417660)
18. Makinen MJ: Colorectal serrated adenocarcinoma. Histopathology 2007, 50:31-50.
19. Yashiro M, Carethers JM, Laghi L, et al.: Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 2001, 60:2676-2683. (Pubitemid 32685854)
20. Soetikno RM, Kaltenbach T, Rouse RV, et al.: Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008, 299:1027-1035. This article describes the importance of recognizing flat and depressed colonic lesions, as these are more likely to be cancerous.
21. Jo W-S, Carethers JM: Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark 2006, 2:51-60.
22. Carethers JM: Prospective evaluation of fluorouracil chemotherapy based on the genetic make-up of colorectal cancer [editorial]. Gut 2006, 55:759-761.
23. Carethers JM, Chauhan DP, Fink D, et al.: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999, 117:123-131. (Pubitemid 29297628)
24. Tajima A, Hess MT, Cabrera BL, et al.: The mismatch repair complex hMutSa recognizes 5-fluoruracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004, 127:1678-1684. (Pubitemid 39575846)
25. Carethers JM, Smith EJ, Behling CA, et al.: Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology 2004, 126:394-401. (Pubitemid 38182296)
26. Steinbach G, Lynch PM, Phillips RK, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952. (Pubitemid 30419089)
27. Giardiello FM, Yang VW, Hylind LM, et al.: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002, 346:1054-1059. (Pubitemid 34984619)
28. Koornstra JJ, Rijcken FE, Oldenhuis CN, et al.: Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2005, 14:1608-1612. (Pubitemid 40995068)